GlassScriptPhysician profile
Melissa Asad
NPI 1497517742
$1,157.75
in general payments reported to CMS, 2019-2025
21 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $226 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $228.86 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $103.04 | 2025 | Airsupra, Breztri |
| Inogen, INC. | $82.65 | 2024-2025 | |
| Glaxosmithkline, LLC. | $78.85 | 2025 | Trelegy Ellipta |
| Genzyme Corporation | $71.02 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.64 | 2025 | Jascayd |
| Grifols USA, LLC | $59.23 | 2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $58.87 | 2025 | Zerbaxa |
| Viatris Specialty LLC | $47.28 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $44.45 | 2025 | Hyqvia |
| Insmed, INC. | $41.72 | 2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $40.35 | 2025 | Zepbound, Mounjaro |
| Pulmonx Corporation | $35.70 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Argenx US, INC. | $35.03 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Actelion Pharmaceuticals US, INC. | $32.82 | 2025 | Opsumit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $26.70 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $24.04 | 2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $23.98 | 2025 | Lumryz |
| Globus Medical, INC. | $21.77 | 2025 | Senza |
| Verona Pharma, INC. | $21.28 | 2025 | Ohtuvayre |
| Amgen INC. | $14.47 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Asad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.